EGFR and neoplasm: Hijacking this EGFR‐specific EV uptake, Kooijmans et al. [167] engineered glycosylphosphatidylinositol (GPI)‐anchored anti‐EGFR nanobodies on the EV surface to promote tumor cell‐specific targeting.